NANDROLONE DECANOATE 200mg/ml

Nandrolone Decanoate 200mg/ml

Molecular Formula:

C28H44O3

Molecular Weight:

428.657 g/mol

Structure:

DESCRIPTION

Nandrolone Decanoate Injection is an injectable anabolic preparation. After injection, nandrolone decanoate is gradually released from the intramuscular depot and subse- quently hydrolyzed into nandrolone.

INDICATIONS

As an anabolic steroid.

Certain cases of disseminated breast cancer in women. Osteoporosis due to androgen deficiency in hypogonadal males.

CONTRAINDICATIONS

Not intended for use in children.

Known or suspected prostatic carcinoma and mammary carcinoma in the male.

Not intended for use in female patients other than those with disseminated breast cancer.

Contraindicated in nephrosis or the nephrotic phase of nephritis, cardiac and renal failure,hypercalcaemia, oedema, jaundice, liver disease with impaired bilirubin excretion, testicular and hepatic carcinoma.

DOSAGE AND DIRECTIONS FOR USE

Nandrolone Decanoate injection should be administered by deep intramuscular injec- tion.

Adult dose: 25 mg to 50 mg every three weeks.

SIDE EFFECTS AND SPECIAL PRECAUTIONS

Virilization which appears in sensitive women as hoarseness, acne, hirustism and in- creased libido; in prepubertal boys as an increased frequency of erections and phallic en- largement, and in girls as an increase of pubic hair and clitoral hypertrophy. Hoarseness may be the first symptom of vocal change which may end in a long-lasting, sometime irreversible deepening of the voice.

O•ther adverse reactions may include:

Oligospermia and decreased ejaculatory volume.

Suppression of ovarian activity, atrophy of the breasts and endometrial tissue Amenorrhea and inhibition of spermatogenesis

Water and salt retention

Premature epiphyseal closure

If signs of virilization develop, treatment should be discontinued

• Increase in nitrogen retention and skeletal weight
• Oedema
• Increased vascularity of the skin
• Increased growth of the bone
• Elderly males may become over stimulated

Patients with the following conditions should be monitored:

Latent or overt cardiac failure, renal dysfunction, hypertension, epilepsy or migraine (or a history of these conditions), since anabolic steroids may induce salt and fluid retention Diabetes, since anabolic steroids may improve the glucose tolerance and decrease the need for insulin or other antidiabetic drugs

Incomplete stature growth, since anabolic steroids may induce hypercalcemia and hy- percalciuria in these patients

Liver dysfunction

DRUG INTERACTIONS

Liver enzyme-inducing agents may reduce the effects of Nandrolone by enhancing its effects in the liver.

PACKAGING

200 mg/ml, 1 ml cartridges

STORAGE

Store in a cool dry place (30 C± 2 C). Protect from light. Warming and rotating the vial between the palms of the hands will redissolve any crystals that may have formed during storage at low temperatures.